Avadel Pharmaceuticals Plc Stock Performance
| AVDL Stock | USD 17.66 0.43 2.38% |
On a scale of 0 to 100, Avadel Pharmaceuticals holds a performance score of 9. The firm shows a Beta (market volatility) of 1.51, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Avadel Pharmaceuticals will likely underperform. Please check Avadel Pharmaceuticals' value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall , to make a quick decision on whether Avadel Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Avadel Pharmaceuticals PLC are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite quite weak fundamental indicators, Avadel Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.05) | Five Day Return 2.72 | Year To Date Return 24.09 | Ten Year Return 50.17 | All Time Return 50.81 |
1 | Gendell Jeffrey L Raises Position in Avadel Pharmaceuticals plc - MarketBeat | 02/23/2024 |
2 | Avadel Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results | 03/05/2024 |
3 | Avadel Pharmaceuticals Posts Quarterly Earnings Results, Misses Expectations By 0.04 EPS | 03/06/2024 |
4 | Avadel Pharmaceuticals Given New 25.00 Price Target at HC Wainwright | 03/08/2024 |
5 | Is Avadel Pharmaceuticals PLC Stock a Smart Value Wednesday - InvestorsObserver | 03/13/2024 |
6 | Is Avadel Pharmaceuticals PLC Stock About to Get Hot Tuesday - InvestorsObserver | 03/19/2024 |
7 | Avadel Pharmaceuticals Reaches New 52-Week High at 17.43 - MarketBeat | 03/22/2024 |
8 | Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference | 04/01/2024 |
9 | Avadel Pharmaceuticals Buy Rating Reaffirmed at Needham Company LLC - Defense World | 04/10/2024 |
10 | Avadel Pharmaceuticals Trading 5.9 percent Higher - MarketBeat | 04/15/2024 |
11 | 106,475 Shares in Avadel Pharmaceuticals plc Purchased by Investors Asset Management of ... - MarketBeat | 04/18/2024 |
| Begin Period Cash Flow | 74 M |
Avadel |
Avadel Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,383 in Avadel Pharmaceuticals PLC on January 26, 2024 and sell it today you would earn a total of 383.00 from holding Avadel Pharmaceuticals PLC or generate 27.69% return on investment over 90 days. Avadel Pharmaceuticals PLC is currently generating 0.4577% in daily expected returns and assumes 3.6449% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Avadel, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Avadel Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avadel Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Avadel Pharmaceuticals PLC, and traders can use it to determine the average amount a Avadel Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1256
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AVDL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.64 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.46 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Avadel Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avadel Pharmaceuticals by adding it to a well-diversified portfolio.
Avadel Pharmaceuticals Fundamentals Growth
Avadel Stock prices reflect investors' perceptions of the future prospects and financial health of Avadel Pharmaceuticals, and Avadel Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avadel Stock performance.
| Return On Equity | -4.81 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (1.28) % | ||||
| Current Valuation | 1.57 B | ||||
| Shares Outstanding | 90.58 M | ||||
| Price To Earning | 61.46 X | ||||
| Price To Book | 16.52 X | ||||
| Price To Sales | 51.79 X | ||||
| Revenue | 27.96 M | ||||
| Gross Profit | 16.59 M | ||||
| EBITDA | (136.08 M) | ||||
| Net Income | (160.28 M) | ||||
| Cash And Equivalents | 104.12 M | ||||
| Cash Per Share | 1.74 X | ||||
| Total Debt | 35.38 M | ||||
| Debt To Equity | 2.63 % | ||||
| Current Ratio | 2.72 X | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | (132.87 M) | ||||
| Earnings Per Share | (2.00) X | ||||
| Market Capitalization | 1.65 B | ||||
| Total Asset | 261.13 M | ||||
| Retained Earnings | (745.5 M) | ||||
| Working Capital | 97.35 M | ||||
| Current Asset | 177.85 M | ||||
| Current Liabilities | 59.19 M | ||||
About Avadel Pharmaceuticals Performance
To evaluate Avadel Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Avadel Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Avadel Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Avadel Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Avadel's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.3 K | 1.4 K | |
| Return On Tangible Assets | (0.66) | (0.62) | |
| Return On Capital Employed | (0.61) | (0.58) | |
| Return On Assets | (0.61) | (0.58) | |
| Return On Equity | (1.83) | (1.92) |
Things to note about Avadel Pharmaceuticals performance evaluation
Checking the ongoing alerts about Avadel Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Avadel Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Avadel Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 27.96 M. Net Loss for the year was (160.28 M) with profit before overhead, payroll, taxes, and interest of 16.59 M. | |
| Avadel Pharmaceuticals PLC currently holds about 104.12 M in cash with (132.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Avadel Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: 106,475 Shares in Avadel Pharmaceuticals plc Purchased by Investors Asset Management of ... - MarketBeat |
- Analyzing Avadel Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avadel Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Avadel Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avadel Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avadel Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Avadel Pharmaceuticals' stock. These opinions can provide insight into Avadel Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Avadel Pharmaceuticals information on this page should be used as a complementary analysis to other Avadel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Avadel Stock analysis
When running Avadel Pharmaceuticals' price analysis, check to measure Avadel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avadel Pharmaceuticals is operating at the current time. Most of Avadel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Avadel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avadel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Avadel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Avadel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.349 | Quarterly Revenue Growth (1.00) | Return On Assets (0.58) | Return On Equity (4.81) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.